Serum AMH levels in women with a history of preeclampsia suggest a role for vascular factors in ovarian aging

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 2, 2014, Pages 579-586

  Yarde, F ^a   Maas, A H E M ^b   Franx, A ^a   Eijkemans, M J C ^a   Drost, J T ^b   Van Rijn, B B ^a,d   Van Eyck, J ^c   Van Der Schouw, Y T ^a   Broekmans, F J M ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Department of Cardiology ^*  (Netherlands)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGING; ANTI-MULLERIAN HORMONE; COHORT STUDIES; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; OVARY; PRE-ECLAMPSIA; PREGNANCY; RETROSPECTIVE STUDIES;

EID: 84893805841     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2902     Document Type: Article

References (40)

1. te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update. 2002;8:141-154.
2. Wood JW. Fecundity and natural fertility in humans. Oxf Rev Reprod Biol. 1989;11:61-109.
3. Spira A. The decline of fecundity with age. Maturitas. 1988;suppl 1:15-22.
4. Broekmans FJ, Faddy MJ, Scheffer G, te Velde ER. Antral follicle counts are related to age at natural fertility loss and age at menopause. Menopause. 2004;11:607-614.
5. Voorhuis M, Onland-Moret NC, van der Schouw YT, Fauser BC, Broekmans FJ. Human studies on genetics of the age at natural menopause: a systematic review. Hum Reprod Update. 2010;16: 364-377.
6. Lambalk CB, van Disseldorp J, de Koning CH, Broekmans FJ. Testing ovarian reserve to predict age at menopause. Maturitas. 2009; 63:280-291.
7. van Disseldorp J., Eijkemans R, Fauser B, Broekmans F. Hypertensive pregnancy complications in poor and normal responders after in vitro fertilization. Fertil Steril. 2010;93:652-657.
8. van Disseldorp J, Broekmans FJ, Peeters PH, Fauser BC, van der Schouw YT. The association between vascular function-related genes and age at natural menopause. Menopause. 2008;15:511-516.
9. Woldringh GH, Frunt MH, Kremer JA, Spaanderman ME. Decreased ovarian reserve relates to pre-eclampsia in IVF/ICSI pregnancies. Hum Reprod. 2006;21:2948-2954.
10. Keegan DA, Krey LC, Chang HC, Noyes N. Increased risk of pregnancy-induced hypertension in young recipients of donated oocytes. Fertil Steril. 2007;87:776-781.
11. Bonomini F, Filippini F, Hayek T, et al. ApolipoproteinEand its role in aging and survival. Exp Gerontol. 2010;45:149-157.
12. Koochmeshgi J, Hosseini-Mazinani SM, Morteza Seifati S, Hosein-Pur-Nobari N, Teimoori-Toolabi L. ApolipoproteinEgenotype and age at menopause. Ann N Y Acad Sci. 2004;1019:564-567.
13. Stolk L, Perry JR, Chasman DI, He C, et al. Meta-Analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet. 2012;44:260-268.
14. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005; 365:785-799.
15. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631-644.
16. Bellamy L, Casas JP, HingoraniAD,Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-Analysis. BMJ. 2007;335:974.
17. Drost JT, Arpaci G, Ottervanger JP, et al. Cardiovascular risk factors in women 10 years post early preeclampsia: the Preeclampsia Risk EValuation in FEMales study (PREVFEM). Eur J Prev Cardiol. 2012;19:1138-1144.
18. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): populationbased retrospective cohort study. Lancet. 2005;366:1797-1803
19. van Rijn BB, NijdamME,BruinseHW,et al. Cardiovascular disease risk factors in women with a history of early-onset preeclampsia. Obstet Gynecol. 2013;121:1040-1048.
20. Veltman-Verhulst SM, van Rijn BB, Westerveld HE, et al. Polycystic ovary syndrome and early-onset preeclampsia: reproductive manifestations of increased cardiovascular risk. Menopause. 2010;17: 990-996.
21. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180:499-506.
22. Rodie VA, Freeman DJ, Sattar N, Greer IA. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis. 2004;175:189-202.
23. Wagner SJ, Barac S, Garovic VD. Hypertensive pregnancy disorders: current concepts. J Clin Hypertens (Greenwich). 2007;9:560-566.
24. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ. 2002;325:157-160.
25. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006;91:4057-4063.
26. van Rooij I, Broekmans FJ, Scheffer GJ, et al. Serum antimüllerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005;83:979-987.
27. Broer SL, Eijkemans MJ, Scheffer GJ, et al. Anti-Müllerian hormone predicts menopause: a long-Term follow-up study in normoovulatory women. J Clin Endocrinol Metab. 2011;96:2532-2539.
28. Tremellen KP, Kolo M, Gilmore A, Lekamge DN. Anti-müllerian hormone as a marker of ovarian reserve.Aust N Z J Obstet Gynaecol. 2005;45:20-24.
29. de Vet A., Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77:357-362.
30. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001; 20:IX-XIV
31. Buckley J, James I. Linear-regression with censored data. Biometrika. 1979;66:429-436.
32. Lin YH, Chiu WC, Wu CH, et al. Antimüllerian hormone and polycystic ovary syndrome. Fertil Steril. 2011;96:230-235.
33. Anderson EL, Fraser A, McNally W, et al. Anti-müllerian hormone is not associated with cardiometabolic risk factors in adolescent females. PLoS One. 2013;8:e64510.
34. Bleil ME, Gregorich SE, McConnell D, Rosen MP, Cedars MI. Does accelerated reproductive aging underlie premenopausal risk for cardiovascular disease? Menopause. 2013;20:1139-1146.
35. Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension. 1989;13:I2-12.
36. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
37. KokHS, van AsseltKM,van der Schouw YT, et al. Heart disease risk determines menopausal age rather than the reverse. J Am Coll Cardiol. 2006;47:1976-1983.
38. Appt SE, Chen H, Clarkson TB, Kaplan JR. Premenopausal antimüllerian hormone concentration is associated with subsequent atherosclerosis. Menopause. 2012;19:1353-1359.
39. Dólleman M, Verschuren WM, Eijkemans MJ, et al. Reproductive and lifestyle determinants of anti-Müllerian hormone in a large population-based study. J Clin Endocrinol Metab. 2013;98:2106-2115.
40. Verschuren WM, Blokstra A, Picavet HS, Smit HA. Cohort profile: the Doetinchem Cohort Study. Int J Epidemiol. 2008;37:1236-1241.